VivoSim Lab (VIVS) Earnings Date & Reports

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

VIVS is expected to report earnings to -227 cents per share on May 22

Q1'25

Est.

$-2.28

Q4'24

Missed

by $2.04

The last earnings report on February 28 showed earnings per share of -228 cents, missing the estimate of -25 cents. With 171.94K shares outstanding, the current market capitalization sits at 3.60M.

View a ticker or compare two or three

Compare

VIVS